Compound I Nephroprotection Against Nephrotoxin-Induced Kidney Injury

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Many drug substances are nephrotoxic, leading to kidney conditions such as acute kidney injury or failure, and existing treatments do not effectively prevent or treat nephrotoxicity induced by nephrotoxins, including both exogenous and endogenous toxins.

Innovation Solution

Compound I, a derivative of cyclosporin A, is used to treat or prevent kidney conditions by administering it before, during, or after exposure to nephrotoxins, thereby protecting renal function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If nephrotoxic drug substances are administered to patients, then therapeutic value is achieved, but kidney injury or failure occurs

Engineering Contradiction:

Improvetherapeutic valueVSAvoidnephrotoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Compound I acts as a protective intermediary substance that mediates between the nephrotoxic drug and kidney tissue. It is administered to patients receiving nephrotoxic drugs to prevent kidney injury, serving as a protective agent that does not interfere with the therapeutic action of the nephrotoxic drug while blocking its harmful effects on renal tissue

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

Compound I is administered before, during, or after exposure to nephrotoxins to prevent kidney injury before it occurs. The compound is given in advance or concurrently with nephrotoxic drug administration to establish protective mechanisms in kidney tissue before damage can occur

Inventive Principle:

Principle #10Preliminary action

2Reliability

If dose of nephrotoxic drug is increased to achieve therapeutic effect, then treatment efficacy improves, but severity of nephrotoxicity increases

Engineering Contradiction:

Improvetreatment efficacyVSAvoidnephrotoxicity severity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Compound I serves as a dose-independent protective mediator that allows full therapeutic dosing of nephrotoxic drugs without concern for proportional increase in kidney damage. The protective effect of Compound I decouples the therapeutic dose from the toxic dose, enabling maximum efficacy dosing with safety margin

Inventive Principle:

Principle #24Intermediary (Mediator)

3Object-affected harmful factors

If nephrotoxic drugs are withheld from patients with renal impairment, then kidney injury is prevented, but therapeutic benefit is lost

Engineering Contradiction:

Improvekidney protectionVSAvoidtherapeutic benefit

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

Compound I enables patients with existing renal impairment to receive nephrotoxic drugs by providing protective mediation. It allows these patients to access therapeutic benefits of nephrotoxic drugs that would otherwise be contraindicated, restoring treatment options for a previously high-risk population

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

Compound I is administered to patients with renal impairment before they receive nephrotoxic drugs to prevent further kidney damage. This preliminary protection enables safe administration of therapeutically necessary drugs in patients who would normally be excluded from such treatment

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20250288639A1Treatment and prevention of nephrotoxin-induced kidney injuries

Publication Date: 2025.09.18 FARSIGHT MEDICAL TECH (SHANGHAI) CO LTD

AI summary

The invention provides for Compound I or a pharmaceutically acceptable salt thereoffor use in the prevention and/or treatment of a kidney condition or disease in a subject exposed to a nephrotoxin capable of inducing said kidney condition or disease.